Chul Kim: PALOMA-3 trial: Significant reduction in IRRs with SC vs. IV in EFGR + NSCLC

Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X:

“PALOMA-3 trial: SC vs. IV amivantamab + lazertinib in EGFR-mutant NSCLC.

Similar ORRs, numerically better PFS, improved OS with SC vs. IV.

Significant reduction in IRRs with SC vs. IV (shorter administration time as well)! A great option for patients. ”